Medivir

Medivir appoints Juserius commercial executive vice president

Thursday, May 17, 2012 10:44 AM

Medivir, a Stockholm-based specialty pharmaceutical company focused on infectious diseases, has appointed Henric Juserius to head the company's commercial activities.

More... »


Medivir receives Fast Track designation from FDA

Wednesday, July 6, 2011 01:21 PM

Medivir’s investigational protease inhibitor TMC435 has received Fast Track designation from the FDA for treatment of chronic hepatitis C (CHC) genotype-1 infection, based on its potential to address medical needs in CHC infection compared to currently approved therapies.

More... »


Medivir presents positive results from ASPIRE phase IIb study for HCV

Friday, May 20, 2011 11:11 AM

Medivir, a research-based specialty pharmaceutical company focused on infectious diseases, has results from the ASPIRE phase IIb study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.

More... »

Medivir to acquire BioPhausia

Tuesday, April 12, 2011 11:18 AM

Swedish pharmaceutical company Medivir will acquire BioPhausia, another Sweden-based firm, in a deal that will "create a platform" for its hepatitis C treatment, according to Pharma Times.

More... »

Medivir releases phase IIb results of TMC435

Tuesday, March 1, 2011 08:00 AM

Medivir, a pharmaceutical company focused on infectious diseases, announced positive results from the phase IIb PILLAR (C205) study of TMC435 in treatment-naive patients with hepatitis C virus (HCV) genotype-1.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.